news
Mounjaro tops Ozempic for weight loss in English real-world data
Real-world data from GlobalData shows 25% of English type 2 diabetes patients on tirzepatide lost at least 15% of their body weight after one year, outperforming semaglutide. Patients on tirzepatide also hit blood sugar targets faster. The findings confirm that the dual-action molecule holds its edge outside controlled trials.
Real-world data from GlobalData shows 25% of English type 2 diabetes patients on tirzepatide lost at least 15% of their body weight after one year, outperforming semaglutide. Patients on tirzepatide also hit blood sugar targets faster. The findings confirm that the dual-action molecule holds its edge outside controlled trials.
The architecture take
Tirzepatide is pulling away from semaglutide outside the pristine conditions of clinical trials. Tirzepatide hits both GIP and GLP-1 receptors, whereas semaglutide only hits GLP-1. That dual agonism does more than quiet food noise in the brain. It improves how the pancreas handles insulin surges and prompts adipose tissue to clear lipids faster. I spent six months assuming the gap between these two compounds would shrink once ordinary patients started managing their own weekly pens. I was wrong. Seeing 25% of patients lose at least 15% of their body weight in routine English clinics settles the debate for me. Eli Lilly holds the metabolic high ground, and Novo Nordisk knows it. I expect the next scramble won't be about raw weight loss anymore. It'll focus on lean muscle preservation and managing nausea when people step up doses too fast.